SOPHiA GENETICS (NASDAQ:SOPH) Director Sells $54,250.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $54,250.00. Following the completion of the transaction, the director owned 103,242 shares in the company, valued at approximately $896,140.56. The trade was a 5.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Down 8.7%

SOPHiA GENETICS stock opened at $8.14 on Friday. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98. The firm has a 50 day moving average price of $6.52 and a 200-day moving average price of $5.45. The company has a market capitalization of $682.86 million, a P/E ratio of -7.08 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on SOPH shares. HC Wainwright raised their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC grew its stake in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the period. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth $50,000. Finally, Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.